Sorrento Therapeutics (LTS:0L85) Research & Development : $186.11 Mil (TTM As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Sorrento Therapeutics Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Sorrento Therapeutics's Research & Development for the three months ended in Jun. 2023 was $33.27 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2023 was $186.11 Mil.

Sorrento Therapeutics Research & Development Historical Data

The historical data trend for Sorrento Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sorrento Therapeutics Research & Development Chart

Sorrento Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Research & Development

Get a 7-Day Free Trial

76.96

106.88

111.34

206.92

221.23

Sorrento Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Research & Development	Get a 7-Day Free Trial															48.47	67.99	41.04	43.81	33.27

Sorrento Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $186.11 Mil.

Sorrento Therapeutics (LTS:0L85) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Sorrento Therapeutics Research & Development Related Terms

Thank you for viewing the detailed overview of Sorrento Therapeutics's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Sorrento Therapeutics (LTS:0L85) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sorrento Therapeutics Inc (LTS:0L85) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

SRNEQ:USA

Address

4955 Directors Place, San Diego, CA, USA, 92121

Website

https://www.sorrentotherapeutics.com

Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.

Sorrento Therapeutics (LTS:0L85) Headlines

No Headlines